Cognitive dysfunction remains one of the most debilitating aspects of schizophrenia, often persisting despite antipsychotic treatment and severely limiting patients' functional recovery. A natural citrus flavonoid may offer a novel therapeutic avenue by targeting the molecular machinery underlying these deficits at the synaptic level.
Researchers demonstrated that naringin, extracted from citrus peels, significantly restored learning and memory function in rats with chemically-induced schizophrenia-like symptoms. The compound reduced inflammatory marker IL-6 and homocysteine levels while protecting hippocampal neurons from damage. Most notably, naringin appeared to rebuild synaptic architecture by increasing postsynaptic density thickness and narrowing synaptic gaps. The mechanism involves modulation of the miR-25-3p/SIK1/CRTC2/CREB1 signaling cascade, which regulates synaptic plasticity and memory formation.
This finding adds to mounting evidence that flavonoids can cross the blood-brain barrier and influence neuroplasticity pathways. Naringin's dual anti-inflammatory and neuroprotective properties align with current understanding that schizophrenia involves both immune dysregulation and synaptic dysfunction. However, the MK-801 model, while useful for studying NMDA receptor hypofunction, captures only certain aspects of schizophrenia's complex pathophysiology. The prophylactic dosing regimen also differs from real-world treatment scenarios where cognitive symptoms emerge gradually. While promising as proof-of-concept for targeting synaptic remodeling in psychiatric disorders, clinical translation would require demonstrating efficacy in established disease states and determining optimal dosing strategies for human patients with variable symptom severity and medication histories.